Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$352.77 - $678.21
Previous CloseN/A
Volume151.62K
Average Volume (3M)293.60K
Market Cap
$37.59B
Enterprise ValueN/A
Total Cash (Recent Filing)$321.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)44.3
Beta0.40
Next Earnings
May 08, 2025EPS Estimate
2.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.89
Shares Outstanding60,760,956
10 Day Avg. Volume346,519
30 Day Avg. Volume293,604
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)89.48
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$751.89Price Target Upside22.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
---
Bulls Say, Bears Say
Bulls Say
Commercial SuccessVyvgart has been consistent beating estimates in gMG while the ongoing launch in CIDP is off to a terrific launch, also surpassing estimates.
Product InnovationThe possible approval of Vyvgart’s prefilled syringe formulation with potential self-administration is anticipated.
Stock RecommendationAnalyst's recommendation is to buy with a price objective set at 774.00 USD, indicating confidence in the stock's future performance.
Bears Say
Market CompetitionManagement is focused on collaborations rather than acquisitions, remaining committed to advancing new molecules into the clinic in the near-term.
Regulatory UncertaintyUpcoming regulatory catalysts that could support additional Vyvgart growth include the potential approval of pre-filled syringes for CIDP in Europe and for gMG and CIDP in Japan and Canada.
---
Ownership Overview
―
Insiders
19.24% Mutual Funds
21.56% Other Institutional Investors
57.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $352.77 and its highest was $678.21 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $37.59B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is May 08, 2025 which is in 46 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Feb 27, 2025. The company reported $11.79 earnings per share for the quarter, beating the consensus estimate of $1.709 by $10.081.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 2.24.
How many shares outstanding does Argenx Se have?
Argenx Se has 60,760,956 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $11.79 in its last earnings report, beating expectations of $1.709. Following the earnings report the stock price went up 0.27%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
---
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$751.89 (22.25% Upside)
$751.89 (22.25% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 53.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.96%
12-Months-Change
Fundamentals
Return on Equity
17.33%
Trailing 12-Months
Asset Growth
36.55%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
ARGX Company Deck
---
ARGX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical milestones, financial growth, and pipeline expansion, indicating strong momentum. However, there were challenges with exchange losses and an operating loss despite revenue growth. Overall, the positive aspects and future outlook outweigh the negatives.Read More>---
ARGX Stock 12 Month Forecast
Average Price Target
$751.89
▲(22.25% Upside)
Technical Analysis
Alnylam Pharma
―
Biogen
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering ARGX
1 Year
1 Year Success Rate
19/21 ratings generated profit
1 Year Average Return
+25.55%
reiterated a buy rating 3 months ago
Copying Allison Bratzel's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +25.55% per trade.
---